AnodyneWiki

Dexmedetomidine

Dexmedetomidine
Dexmedetomidine
Salts
[]
Dexmedetomidine hydrochloride
Dexmedetomidine hydrochloride
Molecular structure drawn from PubChem coordinates
Physical properties
[]
Molecular mass200.28 g/mol [1]
SolubilityFreely soluble in water [1]
Predicted LogP3.1 [1]
Structural Identifiers
[]
Molecular formulaC13H16N2
IUPAC name5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
SMILESCC1=C(C(=CC=C1)[C@H](C)C2=CN=CN2)C
InChIInChI=1S/C13H16N2/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13/h4-8,11H,1-3H3,(H,14,15)/t11-/m0/s1
InChIKeyCUHVIMMYOGQXCV-NSHDSACASA-N
CAS number113775-47-6
UNII67VB76HONO
PubChem CID5311068
Pharmacokinetics[]
Elimination half-life1.8–3.7 hours[3]
MetabolismNear-complete hepatic metabolism to inactive metabolites
ExcretionUrine (95%), feces (4%)
Routes of administrationIntravenous, sublingual, buccal

Dexmedetomidine (also known as Dexmedetomidina, Dexmedetomidinum, Mpv 1440, Mpv-1440, Medetomidine, (s)-, (+)-4-((S)-α,2,3-Trimethylbenzyl)imidazole, 4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole, 4-((1S)-1-(2,3-dimethylphenyl)ethyl)-1H-imidazole, 4-((1S)-1-(2,3-dimethylphenyl)ethyl)-3H-imidazole or 4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-3H-imidazole) is a substance of the phenethylamine class.

Chemistry

Salts []

Dexmedetomidine is typically found in the form of its hydrochloride salt.

 []

Dexmedetomidine is a single defined stereoisomer (optical activity ( + )).

Dexmedetomidine matches Lipinski's rule of five.

Pharmacology

Mechanism of action []

Dexmedetomidine is a specific and selective alpha-2 adrenoceptor agonist. By binding to the presynaptic alpha-2 adrenoceptors, it inhibits the release if norepinephrine, therefore, terminate the propagation of pain signals. Activation of the postsynaptic alpha-2 adrenoceptors inhibits the sympathetic activity decreases blood pressure and heart rate. [1]

Interactions []

Interaction mechanisms documented in (number of interacting drugs):

metabolism / inhibition / induction18
metabolism / inhibition / induction17
inhibition / metabolism4
shared target3 (2 contraindicated)
metabolism3
shared target2 (2 contraindicated)
shared target2 (2 contraindicated)

Medical side effects []

136 side effects listed on drug labels in (dexmedetomidine).

  • Systolic hypertension
  • Respiratory depression
  • Pulmonary function test decreased
  • Hypotension
  • Diastolic hypertension
  • Hypertension
  • Hypertension worsened
  • Hypokalaemia
  • Hypomagnesaemia
  • Constipation
  • Generalised oedema
  • Fluid retention
  • Hypoglycaemia
  • Infarction
  • Withdrawal syndrome
  • Tachycardia
  • Myocardial ischaemia
  • Bradycardia
  • Atrial fibrillation
  • Respiratory failure
  • Hypoventilation
  • Atelectasis
  • Pneumothorax
  • Nausea
  • Vomiting
  • Dry mouth
  • Body temperature increased
  • Anaemia
  • Hyperglycaemia
  • Pleural effusion
  • Chills
  • Rigors
  • Agitation
  • Respiratory rate decreased
  • Hypoxia
  • Post procedural haemorrhage
  • Hypovolaemia
  • Renal failure acute
  • Acute respiratory distress syndrome
  • Acidosis
  • Hypocalcaemia
  • Oliguria
  • Pulmonary oedema
  • Sinus tachycardia
  • Wheezing
  • Abdominal distension
  • Cardiac output decreased
  • Atrioventricular block first degree
  • Metabolic acidosis
  • Hypoalbuminaemia
  • Drug ineffective
  • Oedema peripheral
  • Ventricular tachycardia
  • Abdominal pain
  • Gastrointestinal pain
  • Respiratory acidosis
  • Apnoea
  • Arrhythmia
  • Atrioventricular block
  • Block heart
  • Mental disorder
  • Bronchospasm
  • Cardiovascular disorder
  • Confusional state
  • Feeling abnormal
  • Delirium
  • Diarrhoea
  • Dizziness
  • Dyspnoea
  • Hallucination
  • Headache
  • Cardiac arrest
  • Cardiac disorder
  • Haemorrhage
  • Haemoglobin
  • Hyperbilirubinaemia
  • Hypercapnia
  • Carbon dioxide increased
  • Hyperkalaemia
  • Illusion
  • Nephropathy
  • Myocardial infarction
  • Acute coronary syndrome
  • Neuralgia
  • Neuritis
  • Neuropathy peripheral
  • Pain
  • Convulsion
  • Speech disorder
  • Supraventricular tachycardia
  • Thirst
  • Angiopathy
  • Visual impairment
  • Abnormal vision
  • Ventricular arrhythmia
  • Photopsia
  • Hepatic function abnormal
  • Blood urea increased
  • Urea increased
  • Blood alkaline phosphatase increased
  • Malnutrition
  • Pulmonary congestion
  • Respiratory tract congestion
  • Extrasystoles
  • Hyperpyrexia
  • Light anaesthesia
  • Electrocardiogram T wave inversion
  • Blood pressure fluctuation
  • Hyperhidrosis
  • Anxiety
  • Infection
  • Decubitus ulcer
  • Dermatitis
  • Rash
  • Gastrointestinal disorder
  • Hypernatraemia
  • Body temperature decreased
  • Hypothermia
  • Leukocytosis
  • Mediastinal disorder
  • Pneumonia
  • Pregnancy
  • Septic shock
  • Thrombocytopenia
  • Urinary tract infection
  • Hypophosphataemia
  • Gamma-glutamyltransferase increased
  • Aspartate aminotransferase increased
  • Alanine aminotransferase increased
  • Haemoglobin decreased
  • Sepsis
  • Electrolyte imbalance
  • Sinus arrest
  • Fluid overload
  • Laryngeal pain
  • Somnolence

Indications

  • Agitation
  • Bradycardia

Subjective effects []

bonzi / Dexmedetomidine []

 []

  • Australia: Dexmedetomidine is a Schedule 4.[4]
  • Brazil: Dexmedetomidine is a C1.[5]
  • United States: Dexmedetomidine is Prescription only.[6][7]
  • European Union: Dexmedetomidine is Prescription only.[8][9][10]
  • Other: Dexmedetomidine is a Rx-only.

See also []

External links []

References []

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 5311068, Dexmedetomidine. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/5311068
  2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Dexmedetomidine. UNII: 67VB76HONO. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/67VB76HONO
  3. Precedex-Label. www.accessdata.fda.gov. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021038s061lbl.pdf
  4. DEXMEDETOMIDINE FRESENIUS (Fresenius Kabi Australia Pty Ltd). Department of Health and Aged Care. https://www.tga.gov.au/resources/prescription-medicines-registrations/dexmedetomidine-fresenius-fresenius-kabi-australia-pty-ltd
  5. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 2023-03-31. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
  6. Precedex- dexmedetomidine hydrochloride injection, solution. DailyMed. 2 March 2022. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4419162d-81d4-49bd-96de-1729440bdb74
  7. Igalmi- dexmedetomidine film. DailyMed. 14 December 2022. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99476e8c-2527-4cb0-9d67-9f9cd91343c6
  8. Sileo EPAR. European Medicines Agency. 7 July 2015. https://www.ema.europa.eu/en/medicines/veterinary/EPAR/sileo
  9. Dexdomitor EPAR. European Medicines Agency (EMA). 14 December 2009. https://www.ema.europa.eu/en/medicines/veterinary/EPAR/dexdomitor
  10. Dexdomitor PI. Union Register of medicinal products. 5 September 2002. https://ec.europa.eu/health/documents/community-register/html/v033.htm

Data sources []

SourceStatusUpdated (UTC)
dosingmissing (no dosing statistics)2026-11-20 06:05:54
drugspromissing (no DrugsPRO reagent data)2026-11-20 06:05:50
erowidmissing (no Erowid substance of that name)2026-11-20 06:05:50
gsrsok2026-11-20 06:05:51
hmdbmissing (hmdb.ca refused automated access to HMDB0014771)2026-11-20 06:05:50
keggok2026-11-20 06:05:52
pubchemok2026-11-20 06:05:50
redditmissing (no r/tripreports posts mention it)2026-11-20 06:05:50
siderok2026-11-20 06:05:51
structureok2026-11-20 06:05:50
wikipediaok2026-11-20 06:05:51